Experts Dissect Key Findings for Progressive Gastric and GEJ Cancers
Christin L. Melton, ELS
Published: Friday, Sep 20, 2019
Johanna C. Bendell, MD
Although chemotherapy combinations remain standard first-line therapy for advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, strategies for progressive disease have shifted to include antiangiogenic agents and immunotherapy.
... to read the full story